Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at "European Huntington's Disease Network (EHDN) plenary meeting 2018"

POSTER

Active Biotech regains global rights to development and commercialization of laquinimod

PRESS RELEASE

ANYARA Tumor Targeting Immunotherapy

ANYARA: Clinical Development

Develops Novel Treatments for Cancer and Neurodegenerative Diseases

ABOUT US

An Experienced Team — Building Solid Partnerships

MANAGEMENT

Neurodegeneration & Inflammation

Effective treatments of diseases with high medical need

Active Biotech focuses on the research and development of pharmaceuticals in therapeutic areas with high medical need, in which the immune system is of central importance. The project portfolio comprises small, orally active immunomodulatory molecules and antibody-based immunotherapy being developed for the treatment of cancer, as well as neurodegenerative diseases and inflammation.

Diseases where the immune system is of central importance